KRAS mutation that matters - oncology
Oncology │ KRAS

Unlock KRAS G12C for treatment in lung and colorectal cancer

KRAS G12C - the key to new treatment options

The therascreen KRAS RGQ PCR Kit is an FDA-approved companion diagnostic (CDx) test to detect mutations in the KRAS oncogene. The test specifically identifies patients that may be eligible for treatment with the following drugs, based on the detection of the KRAS G12C mutation:

Reliably detect the KRAS mutation that matters

The therascreen KRAS RGQ PCR Kit is a unique molecular test, based on the detection of specific KRAS mutations in tumor DNA isolated from formalin-fixed paraffin-embedded (FFPE) NSCLC or CRC tumor tissue. The kit targets seven mutations in codons 12 and 13 of the KRAS gene (G12A, G12D, G12R, G12C, G12S, G12V and G13D).

Get the details
The therascreen KRAS RGQ PCR Kit is a unique molecular test, based on the detection of specific KRAS mutations in tumor DNA isolated from formalin-fixed paraffin-embedded (FFPE) NSCLC or CRC tumor tissue.
Start testing for KRAS G12C
Start testing for KRAS G12C

Find a laboratory offering testing using the therascreen KRAS RGQ PCR Kit to start making informed NSCLC and CRC treatment decisions.

Find a lab
Solutions for precision healthcare

QIAGEN’s therascreen kits allow you to access relevant genomic information for each patient and use it to make the best treatment decisions possible.

Browse our products
Solutions for precision healthcare - KRAS
The therascreen KRAS RGQ PCR Kit is intended for in vitro diagnostic use.